03-26-2020, 11:10 AM
Recent study from China. Not showing efficacy but very small and maybe losing something in translation.
Abstract re. Hydroxychloroquine.
浙江大学学报（医学版） 2020 年 3 月
JOURNAL OF ZHEJIANG UNIVERSITY March 2020
SONG Shuli, ZHANG Dandan, QIAN Zhiping, LI Tao, SHEN Yinzhong, LU Hongzhou
(Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan
University, Shanghai 201508, China)
Corresponding author: LU Hongzhou, E-mail: luhongzhou@fudan.edu.cn, https://orcid.org/0000-0002-
8308-5534
[Abstract] Objective: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the
treatment of patients with common coronavirus disease-19 (COVID-19). Methods:
We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed
consent at Shanghai Public Health Clinical Center. The patients were randomized 1:1 to HCQ
group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days
plus conventional treatments, while those in the control group were given conventional treatment
only. The primary endpoint was negative conversion rate of COVID-19 nucleic acid in respiratory
pharyngeal swab on days 7 after randomization. This study has been approved by the ethics
committee of Shanghai public health clinical center and registered online (NCT04261517). Results: One
patient in HCQ group developed to severe during the treatment. On day 7, COVID-19 nucleic acid of
throat swabs was negative in 13 (86.7%) cases in the HCQ group and
14 (93.3%) cases in the control group (P＞0.05). The median duration from hospitalization to
virus nucleic acid negative conservation was 4 (1-9) days in HCQ group, which is comparable to
that in the control group [2 (1-4) days, (U = 83.5, P ＞ 0.05)]. The median time for body
temperature normalization in HCQ group was 1 (0-2) after hospitalization, which was also
comparable to that in the control group 1 (0-3). Radiological progression was shown on CT
images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all
patients showed improvement in follow-up examination. Four cases (26.7%) of the HCQ group
and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (P＞
0.05). Conclusions: The prognosis of common COVID-19 patients is good. Larger sample size
study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent
research should determine better endpoint and fully consider the feasibility of experiments such as
sample size. [Key words] Severe acute respiratory syndrome coronavirus 2; Corona virus disease-19;
Novel
coronavirus pneumonia; Hydroxychloroquine; Treatment outcome; Safety
2019 年 12 月，湖北省武汉市陆续出现多例不明原因肺炎，并迅速蔓延
[1]。2020 年 1 月
31 日，WHO 将这次疫情列为国际关注的突发公共卫生事件
[2]。基因序列分析结果显示，本次
疫情的病原体为β属冠状病毒，与严重急性呼吸综合征（severe acute respiratory
syndrome, SARS）病毒高度同源，国际病毒分类委员会将其命名为严重急性呼吸综合征冠
Abstract re. Hydroxychloroquine.
浙江大学学报（医学版） 2020 年 3 月
JOURNAL OF ZHEJIANG UNIVERSITY March 2020
SONG Shuli, ZHANG Dandan, QIAN Zhiping, LI Tao, SHEN Yinzhong, LU Hongzhou
(Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan
University, Shanghai 201508, China)
Corresponding author: LU Hongzhou, E-mail: luhongzhou@fudan.edu.cn, https://orcid.org/0000-0002-
8308-5534
[Abstract] Objective: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the
treatment of patients with common coronavirus disease-19 (COVID-19). Methods:
We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed
consent at Shanghai Public Health Clinical Center. The patients were randomized 1:1 to HCQ
group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days
plus conventional treatments, while those in the control group were given conventional treatment
only. The primary endpoint was negative conversion rate of COVID-19 nucleic acid in respiratory
pharyngeal swab on days 7 after randomization. This study has been approved by the ethics
committee of Shanghai public health clinical center and registered online (NCT04261517). Results: One
patient in HCQ group developed to severe during the treatment. On day 7, COVID-19 nucleic acid of
throat swabs was negative in 13 (86.7%) cases in the HCQ group and
14 (93.3%) cases in the control group (P＞0.05). The median duration from hospitalization to
virus nucleic acid negative conservation was 4 (1-9) days in HCQ group, which is comparable to
that in the control group [2 (1-4) days, (U = 83.5, P ＞ 0.05)]. The median time for body
temperature normalization in HCQ group was 1 (0-2) after hospitalization, which was also
comparable to that in the control group 1 (0-3). Radiological progression was shown on CT
images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all
patients showed improvement in follow-up examination. Four cases (26.7%) of the HCQ group
and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (P＞
0.05). Conclusions: The prognosis of common COVID-19 patients is good. Larger sample size
study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent
research should determine better endpoint and fully consider the feasibility of experiments such as
sample size. [Key words] Severe acute respiratory syndrome coronavirus 2; Corona virus disease-19;
Novel
coronavirus pneumonia; Hydroxychloroquine; Treatment outcome; Safety
2019 年 12 月，湖北省武汉市陆续出现多例不明原因肺炎，并迅速蔓延
[1]。2020 年 1 月
31 日，WHO 将这次疫情列为国际关注的突发公共卫生事件
[2]。基因序列分析结果显示，本次
疫情的病原体为β属冠状病毒，与严重急性呼吸综合征（severe acute respiratory
syndrome, SARS）病毒高度同源，国际病毒分类委员会将其命名为严重急性呼吸综合征冠